We evaluated the use of a semi-automated processing technique to salvage red blood cells from pediatric bone marrow donors to minimize the risk of severe anemia following bone marrow harvest and ABO incompatibility in the recipient. Sixty healthy, HLA-matched, pediatric donors of bone marrow hematopoietic cells with a median age 8.0 years (2-19) were studied. Thirteen of the donor-recipient pairs were ABO incompatible. There were 60 recipients with a median age of 8. ؉ cell population, without affecting hematopoietic reconstitution.
Healthy pediatric donors of hematopoietic stem cells are at risk of severe anemia after bone marrow harvest.
1,2 Several approaches have been used to prevent post-harvest anemia. In adult patients the ability to donate autologous blood prior to the harvest is the most common approach, and is used by the NMDP. 3 This method is difficult to practice in pediatric patients because of their size, small blood volume and difficulty in accessing adequate veins. Others have utilized allogeneic blood bank derived transfusions with the accompanying risk of transmission of viral infection. Martinez et al 4 has reported the use of erythropoietin prior to harvesting, in combination with iron supplementation. Our study prospectively evaluated the salvage of red cells from the harvest specimen and subsequent reinfusion to the donor avoiding the risk of allogeneic red cell transfusions, and also preventing ABO incompatibility with the bone marrow recipient.
Patients and methods
From March 1992 to August 1998, 60 pediatric HLAmatched donors for patients undergoing allogeneic transplants at Children's Memorial Hospital were entered on this trial. Donors or their legal guardians signed written informed consent for the bone marrow harvest according to the Institutional Review Board guidelines. There were 60 donors; 33 males and 27 females, with a mean age of 9.1 years (median 8.0, range 2-19 years). All donors were HLA-matched. There were 13 donor-recipient pairs who were ABO incompatible. There were 60 recipients, 34 males and 26 females. The mean age was 9.8 years (median 9.0, range 4 months to 25 years) and the mean weight was 31 kg (median 25.7 kg, range 6-82 kg).
Bone marrow harvest
Marrow was harvested under general anesthesia from both posterior iliac crests, using the method reported by Rowley. 5 Specimens were collected in tissue culture medium 199 phenol-free (Bio-Whittaker, Walkersville, MD, USA) in 44 patients and with red phenol in 16 (Life Technologies, Grand Island, NY, USA). The specimens were mixed with preservative-free heparin and filtered in the operating room with a disposable bone marrow harvest kit from Baxter (Baxter Fenwall, Deerfield, IL, USA). During the harvest donors received i.v. fluids at a ratio of 3 cm 3 to 1 cm 3 of marrow harvested, given from the start of the procedure until the red cells were ready for infusion.
Bone marrow processing and red cell salvage
Marrow was delivered to the processing laboratory and samples for cell count and differential were obtained using a Coulter model JT (Coulter Electronics, Hialeah, FL, USA). CD34 ϩ cell count was calculated by flow cytometry on a FacSort (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA), with initial gating on the mononuclear cell population as defined by CD45FITC/CD14 PE staining, and evaluating for CD34
ϩ FITC/CD38 ϩ PE, and HLA-DR ϩ FITC/CD34 ϩ PE stained populations. The monoclonal antibodies used were obtained from BDIS and Immunotech (Marseilles, France). Cell viability was assessed using the Trypan blue exclusion method and light microscopy. Hematocrit and bacteriological cultures were performed with standard techniques. Colony assays were set up on 24-well culture plates at a cell concentration of 0.5 ϫ 10 6 cell/ml using Methocult H4433 (Stem Cell Technologies, Vancouver, BC, Canada) which comes enriched with erythropoietin and l-glutamine and incubated at 37°C with 5% CO 2 . Cultures were read on days 7 and 14 using an inverted microscope. Colonies were scored based on morphologic criteria. 5 Bone marrow was processed in a semi-automated Stericell (Terumo, Elkdone, MD, USA) centrifugal cell processor. This equipment is pre-programmed for buffy-coat collection, density gradient separation and cell washing. All the marrow harvests were processed by density gradient separation, as described previously by Hillyer et al, 6 Pierelli et al and Kletzel et al. 8 Samples of the processed cells were obtained again for cell count, CD34 ϩ cell count, colony assay and viability. The salvaged red cells were sent to the blood bank for typing and cross-matching and then transfused into the donor via a peripheral vein using standard blood transfusion techniques.
Results
Sixty donors with a median age of 8.0 years were harvested and their bone marrow processed according to the protocol described. The median harvested volume was 608 Ϯ 40.42 ml (278-1409) and the volume infused was 174 Ϯ 10.75 ml (30.2-380) (P Ͻ 0.0001), which represents a decrease of 72% (Figure 1 ). The median total nucleated cell count harvested was 1.6 ϫ 10 10 /kg Ϯ 0.1 (0.56-3.2) while the median total nucleated cell count infused to the patient was 6.9 ϫ their recovered red cells. There were no episodes of hypotension and the median time from harvest to infusion of recovered red cells was 2.3 h (range 2.0-4.0). All donors were discharged the same day from the day hospital without any problems. Engraftment was defined as an ANC Ͼ 500 l for 3 consecutive days, which was achieved in 54 recipients at a median of 17 days (10-71). Platelet engraftment was defined as a platelet count Ͼ 20.0/l without platelet support and this was achieved in 46 of the transplanted patients at a median of 23 days (10-168). Death from either transplant-related toxicity or recurrent disease was the reason for engraftment failure. Of those who achieved engraftment, 52 had allogeneic engraftment with greater than 95% donor origin cells detected by restriction The ability of this technique to enrich the CD34 ϩ cell pool after Ficoll-Hypaque gradient centrifugation demonstrating a statistically significant enrichment P Ͻ 0.0001 is shown. length polymorphism (RFLP), while two patients recovered with autologous cells. There were no instances of ABO incompatibility in the marrow recipients.
Statistical analysis
The analysis was performed on Prism version 2.0 (GraphPad, San Diego, CA, USA), and the comparative analysis was done with the t-test to determine the P value where a statistical difference was detected at the level of 0.05. The s.e.m., the s.d. and the bar figures were calculated and drawn utilizing the same program.
Discussion
Prevention of exposure of healthy pediatric donors to unnecessary blood products should be the standard of care in the field of stem cell transplantation. The risk of postbone marrow harvest anemia is presumed to be of minimal consequence but is poorly studied. In adult donors who have less than 20% of their blood volume removed it is common practice to allow them to donate autologous blood several weeks prior to their bone marrow harvest. This practice is not feasible in young children due to their low blood volume and poor venous access, as well as regulatory issues that forbid this practice. In pediatric patients several alternative approaches have been taken. Some investigators transfuse their donors with blood from the blood bank, others tolerate anemia and place the donors on supplemental iron and allow them to recover spontaneously. Chan et al 9 reported on the use of autologous blood recovered from harvested marrow in nine pediatric patients using a simple inverted centrifuge while the bone marrow was being harvested. He reported no complications but in two of their harvests a great loss of nucleated cells was encountered. Martinez et al 4 described the use of rh-EPO plus iron 3 weeks prior to harvesting in 11 patients. They reported increments in hematocrit of between 5 and 18%, mean 10.6%, which allowed for the avoidance of transfusions. 4 This approach was successful but does expose the donor to cytokines, which may have potential long-term consequences. In addition, the cost of the cytokine is significant, and the pain inflicted on the child who receives the daily injections must be considered.
We have used an approach to salvage red blood cells analogous to techniques used by surgeons in the operating room to avoid the need for allogeneic red cell transfusion. 10 The equipment that we use is a semi-automated closed system, which eliminates the risk of bacteriological contamination. The process also eliminates the risk of allogeneic red cell transfusion and does not interfere with engraftment. As shown by our results, this process decreased by 72% the volume infused, practically eliminated the requirement for red cell transfusion and enriched both the mononuclear cell pool and the CD34 ϩ cells. The only significant loss of cells is the expected decrease in total nucleated cell count due to the intended removal of mature polymorphonuclear cells. Another advantage of this method is the prevention of ABO incompatibility in the marrow recipient, which can carry a high morbidity during transplantation. One possible objection to this approach may be the delay in infusing the marrow to allow for processing. In our hands this process takes 2-3 h depending on the volume processed and can be done on the same day of the harvest. Another potential objection is exposure to Ficoll, but this is eliminated with a cell-washing step. The issue of cost is important but we believe that the benefits of this approach out-weigh the cost, which are not excessive, especially compared to recombinant erythropoietin or even allogeneic red cell transfusion.
In conclusion, red cell salvage in a semi-automated closed system is a safe, cost-effective method for red cell depletion of bone marrow and reduces the risk of post-bone marrow harvest anemia in pediatric donors. In addition, this method decreases the volume infused to the recipient, pre-venting volume overload and enriches the mononuclear and CD34 ϩ cell population without affecting hematopoietic reconstitution.
